In Depth 27 Oct 2023 Big pharma monopolies: major antitrust cases over the past decade Antitrust laws are put in place to prevent unlawful activities like price fixing, as well as monopolies from forming, typically tied to big pharma. If these powerful companies were to swallow smaller biotechs in an attempt to fix prices, it would stifle competition, result in limited options for consumers, thereby leading to a rise in […] October 27, 2023 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 27 Oct 2023Beyond Biotech podcast 69 – improving access to cell and gene therapy This week, our guest on the podcast is Jason C. Foster, CEO of Ori Biotech. Ori is a London, U.K. and New Jersey, U.S. based manufacturing technology company pioneering flexible process discovery with translation and scalable commercialization of cell and gene therapies (CGT), increasing access to these innovative treatments. Ori has developed a proprietary, full […] October 27, 2023 Share WhatsApp Twitter Linkedin Email
In Depth 26 Oct 2023 Behind closed doors: The unseen controversies and scandals in Alzheimer’s drug trials Alzheimer’s disease is the most common form of dementia – which currently affects more than 55 million people globally – making up 60% to 70% of cases. It is a complex disease, encompassing multiple interrelated and progressive destructive processes in the brain, resulting in neuron damage that extends to parts of the brain that enable […] October 26, 2023 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Opinion 25 Oct 2023 Microbiome: are we ready for third generation live biotherapeutics? The microbiome sector has come a long way. From liquidizing fecal matter in a kitchen appliance for direct insertion into the intestine to the encapsulation of dried matter for oral delivery; and now to the creation of live biotherapeutics, single drug products of multiple bacterial strains. The application of microbiome therapeutics is also broadening – […] October 25, 2023 - 11 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Oct 2023 Seven molecular glue startups looking to stick around in the biotech industry Since they were discovered around three decades ago, molecular glues have come a very long way as a therapeutic option for several different disease areas, including cancer and neurodegenerative disorders. Now, there are a rising number of molecular glue companies hoping to show clinical success with their candidates. The term molecular glue refers to a […] October 24, 2023 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Expert Advice 23 Oct 2023 Top 10 tips from an expert on how to start an early phase clinical trial Early phase clinical trials can be complicated and time-consuming, with their success dependent on several different factors. The outcome of these early phase clinical trials will determine the future of your drug development project, and so ensuring safety and efficiency at every step since the start is vital for its overall success. The clinical operations […] October 23, 2023 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 20 Oct 2023 Is Africa ready to become the next big biopharma and vaccine manufacturing destination? Localizing pharma manufacturing worldwide is an extremely important step, and it holds particular significance for Africa. The continent is more vulnerable to disease burdens and lags behind other continents when it comes to vaccine and general healthcare access. Localized manufacturing could help people in Africa gain easier and more affordable access to vaccines and other […] October 20, 2023 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 20 Oct 2023Beyond Biotech podcast 68 – rejuvenation with stem cells This week, our guest on the podcast is Mark Kotter, founder of clock.bio. clock.bio, a sister company to bit.bio, which Kotter also founded and is the CEO of, aims to extend and improve quality of life by reversing the harmful effects of time in our cells, harnessing the regenerative capabilities of human pluripotent stem cells […] October 20, 2023 Share WhatsApp Twitter Linkedin Email
In Depth 19 Oct 2023 Biotech’s battle against NASH: The ongoing pursuit of an effective treatment NASH is one of the most common reasons for a patients receiving a liver transplant. The condition is a severe form of non-alcoholic fatty liver disease (NAFLD), whereby fat builds up on the liver, potentially leading to liver damage or cirrhosis. And, yet, despite the severity of the disease, there are still no approved NASH […] October 19, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 16 Oct 2023 Blockchain-based biotech: is this a viable financing method? At a time when biotechs are scrambling to raise funds, a new way for startups to secure investments is emerging: leveraging cryptocurrency. The motive behind decentralized financing seems pretty ambitious – to democratize funding in healthcare. But does it live up to the hype? With VitaDAO – a decentralized collective that funds early-stage startups looking […] October 16, 2023 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 13 Oct 2023 How close are we to a cure for metastatic breast cancer? Currently considered an incurable disease, there is a lot of work being done around developing better treatment options for metastatic breast cancer, and, ultimately, a cure. Numerous promising candidates are in clinical trials, all with the hope of progressing toward U.S. Food and Drug Administration (FDA) approval. According to the World Health Organization (WHO), 2.3 […] October 13, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 13 Oct 2023Beyond Biotech podcast 67 – natural killer cells This week, we speak to Artiva Biotherapeutics’ CEO, Fred Aslan, M.D. The company has demonstrated the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials. In August, the company announced FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell […] October 13, 2023 Share WhatsApp Twitter Linkedin Email